文献速递神经核医学肿瘤 PET/CT

FAPI 显像探测脑转移灶的系统评价与荟萃分析

Revealing the hidden: A systematic review and meta-analysis of FAPI-based tracers imaging for brain metastatic lesions.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2025-10-07

该系统评价纳入截至 2025 年 4 月的 24 项研究、逾 115 例患者和 291 个以上病灶,比较 FAPI 与 [18F]FDG PET 对脑转移灶的检出率。FAPI 检出率为 87.9%(95%CI 76.1-94.3%),[18F]FDG 为 46.3%(95%CI 30.6-62.8%),OR 为 10.78(95%CI 5.15-22.55),FAPI 的靶本比(TBR)更高。

要点

  • FAPI 对脑转移灶检出率 87.9%,明显高于 [18F]FDG 的 46.3%。
  • FAPI 的靶本比(TBR)高于 [18F]FDG PET/CT(SMD 1.51)。
  • 作者认为 FAPI 可能优于传统方法,但需进一步验证临床有效性。

核心结论

  • FAPI 类示踪剂在识别脑转移灶方面似乎优于 [18F]FDG PET。
  • FAPI 显像有潜力成为优于传统方法的诊断工具。
  • 仍需进一步研究验证其临床有效性。

研究设计与样本

  • 系统评价与荟萃分析,检索 Google Scholar、PubMed 和 Scopus 截至 2025 年 4 月发表的研究。
  • 纳入评估 FAPI 类 PET 对脑转移诊断性能的研究,主要基于标准化摄取值(SUV)和靶本比(TBR)评价。
  • 共纳入 24 项研究,涉及逾 115 例患者和 291 个以上病灶。

主要发现

  • FAPI 类显像检出 87.9% 的病灶(95%CI 76.1-94.3%,p < 0.001)。
  • [18F]FDG 的检出率为 46.3%(95%CI 30.6-62.8%,p = 0.667)。
  • 两种方法检出率比较的 OR 为 10.78(95%CI 5.15-22.55,p < 0.001)。
  • FAPI 示踪剂靶本比高于 [18F]FDG PET/CT(SMD 1.51,95%CI 0.86-2.16,p < 0.001)。

关键数值与推荐

  • 主要终点为 FAPI 类示踪剂的检出率。
  • 纳入研究主要考察 FAPI 基于 SUV 和 TBR 的表现。

临床怎么用

  • 对疑似脑转移灶的评估,FAPI 显像可能提供高于 [18F]FDG PET/CT 的检出率和靶本比。
  • 在 [18F]FDG 因正常脑组织生理性摄取高而难以区分病灶时,可考虑 FAPI 显像。
  • 作者提示其临床有效性尚待进一步研究验证,应用时应结合具体临床情况。

局限性

  • 作者指出需进一步研究验证 FAPI 显像的临床有效性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Regarding the assessment of brain metastatic lesions, [18F]FDG PET/CT encounters challenges due to heightened physiological uptake in normal brain tissue, resulting in poor tumor-to-background ratios (TBR). Detecting brain metastases accurately has long been a challenge with standard imaging methods. The elevated physiological uptake of [18F]FDG in normal brain parenchyma limits its ability to distinguish metastatic lesions owing to poor tumor-to-background contrast. On the other hand, radiolabeled fibroblast activation protein inhibitors (FAPI) have emerged as a newer imaging tracer, showing promise. This study aimed to collect available literature to assess FAPI's ability to detect brain metastases across various cancer types. METHODS: We reviewed studies published up to April 2025, utilizing different databases, including Google Scholar, PubMed, and Scopus, primarily examining the performance of FAPI based on standardized uptake values (SUVs) and TBRs. Studies focusing on the diagnostic performance of FAPI-based PET for brain metastasis were included. The primary endpoint was the detection rate of FAPI-based tracers. RESULTS: In 24 studies involving over 115 patients and more than 291 lesions, FAPI-based imaging detected of 87.9% lesions (95% CI: 76.1-94.3%, p < 0.001) compared to [18F]FDG by the detection rate of 46.3% (95% CI: 30.6-62.8%, p = 0.667). The comparison of detection rates of these modalities showed an OR of 10.78 (95% CI: 5.15-22.55, p < 0.001). FAPI radiotracers exhibited higher TBR compared to [18F]FDG PET/CT (SMD: 1.51, 95% CI: 0.86-2.16, p < 0.001). CONCLUSION: In conclusion, FAPI-based tracers seem to surpass [18F]FDG PET in identifying brain metastases. FAPI imaging can potentially serve as a diagnostic tool that offers benefits over traditional methods. Further research is needed to verify its clinical effectiveness.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Sadeghpour S, Aghaee A, Ahmadzadehfar H, et al. Revealing the hidden: A systematic review and meta-analysis of FAPI-based tracers imaging for brain metastatic lesions. Eur J Nucl Med Mol Imaging. 2025. PMID: 41055767. doi:10.1007/s00259-025-07576-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。